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Stability of levetiracetam oral solution repackaged in oral plastic syringes 
Abstract 
Purpose The long-term stability of levetiracetam solution in oral syringes was investigated in order to 
define a suitable beyond-use date and demonstrate the feasibility of storing prepared syringes for 
extended periods as an alternative to commercial levetiracetam unit dose cups. 
Methods Levetiracetam oral solution (100 mg/mL) was drawn into 1- and 10-mL amber polypropylene 
oral syringes. Triplicate samples of the syringe preparations were stored at refrigeration (2–8 °C) or room 
temperature (20–25 °C) and evaluated at monthly intervals for up to six months. At each time point, the 
samples were visually inspected and levetiracetam stability was assessed via pH measurement and high-
performance liquid chromatography (HPLC). A short-term forced degradation study was conducted to 
confirm that the HPLC assay method was stability indicating. 
Results Over the six-month storage period, there was no significant change in either the visual appearance 
or pH of any of the levetiracetam samples. The results of serial HPLC assessment indicated that at least 
97% of the initial levetiracetam concentration was retained in all samples of 1- and 10-mL oral syringes at 
both refrigeration and room temperature. Although this study was conducted using a generic product, the 
stability data obtained may be applied in repackaging decisions regarding other generic formulations of 
levetiracetam with similar excipient compositions. 
Conclusion Commercial levetiracetam 100-mg/mL oral solution was stable for up to six months in amber 
polypropylene oral syringes stored at both refrigeration and room temperature conditions. 
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ABSTRACT 
Purpose. With the increased use of levetiracetam oral solution in hospitals, there is a need 
to repackage this solution product in oral plastic syringes to facilitate dispensing and dosing. 
This study was designed to evaluate the long-term stability of levetiracetam solution in oral 
syringes with an intention to set a suitable beyond-use date. 
 
Methods. Commercially available levetiracetam oral solution (100 mg/mL) was drawn 
into 1-mL and 10-mL amber polypropylene oral syringes. The samples were stored at 
refrigeration (2° – 8C) or room temperature (20° – 25C), and they were pulled for 
evaluation at monthly intervals for up to six months. At each time point, the samples were 
evaluated by visual inspection, pH measurement, and high performance liquid 
chromatography (HPLC). A separate forced stability study was conducted to confirm that 
the HPLC method was stability indicating.    
 
Results. Over the period of six months storage, there was no significant change in visual 
appearance or pH for any of the levetiracetam stability samples. The HPLC results 
indicated that levetiracetam retained 97-108% of the initial concentration in 1-mL and 10-
mL oral syringes at both refrigeration and room temperature. 
 
Conclusion. Commercial levetiracetam 100 mg/mL oral solution was stable for up to six 
months in amber polypropylene oral syringes stored at both refrigeration and room 
temperature conditions. 
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INTRODUCTION 
Levetiracetam is an anticonvulsant used as an adjunctive therapy in the treatment 
of partial-onset seizures, myoclonic seizures, primary generalized tonic-clonic seizures, 
and idiopathic generalized epilepsy in both adults and children.1 An oral solution product 
of levetiracetam, 100 mg/mL, is available commercially for patients with difficulty 
swallowing tablets. 1 This solution product has become frequently prescribed in hospitals, 
which prompts the need to repackage the product into oral plastic syringes to facilitate 
dispensing and dosing. Unfortunately, there is no published data concerning the stability 
of the commercial levetiracetam oral solution in commonly used oral plastic syringes. 
 The purpose of this study is to evaluate the long-term stability of levetiracetam oral 
solution (100 mg/mL) in oral plastic syringes for up to six months. A commonly used oral 
amber polypropylene syringe with a matching tip was chosen as the packaging device for 
the study. The 1-mL and 10-mL syringe volumes were selected to bracket the typical dose 
range of levetiracetam oral solution.1 Both refrigeration and room temperature storage 
conditions were included in this study to provide options and flexibility for the pharmacy.  
It is worth mentioning that a few manufacturers market the levetiracetam solution 
in unit-dose cups. These unit-dose cups provide convenience in dispensing, but the dose 
volume is not as accurate as the oral syringes. It is common that a significant volume of 
solution is retained in the cup after oral administration. Accurate dose is always important, 
especially for the anticonvulsant in this case. In addition, the oral syringes can be used to 
deliver pediatric doses which are below the lowest volume of the unit-dose cups available. 
Finally, with the ever changing landscape on drug shortages, institutional pharmacies are 
frequently called on to create temporary supplies of repackaged medications. With the 
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accuracy and broad application of the oral syringes, they would provide a satisfactory 
substitution for the unit-dose cups in case of shortages. 
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METHODS 
Stability Study 
 Commercially available levetiracetam 100 mg/mL oral solutiona was drawn into 1-
mL and 10-mL amber polypropylene oral syringesb. The syringes tips were capped 
immediately afterwards. The filled syringes were stored at refrigeration (2° – 8°C) and 
room temperature conditions (20° – 25°C). Triplicate samples were prepared for each 
syringe size, storage condition, and time points. 
 Stability evaluation was performed immediately after preparation and after 1, 2, 3, 
4, 5, and 6 months of storage. At every time point, triplicate syringe samples each of 1-mL 
and 10-mL from both temperature conditions were pulled for evaluation. The entire content 
of each syringe sample was first expelled into a clear glass vial for visual inspection against 
a light background for clarity, color, precipitation, and microbial growth. The same sample 
was then subjected to pH measurementc. Finally, a 200 µL aliquot from each sample was 
diluted with purified water in a 100-mL volumetric flask and analyzed by HPLC for 
chemical stability (three injections for each of the triplicate samples). 
High-performance Liquid Chromatography (HPLC) 
 The HPLC analysis was performed using a Shimadzu model LC-2010A instrumentd. 
The chromatographic parameters were adapted from a stability indicating assay previously 
published by Saravanan et al.2 A YMC C18 columne was used and maintained at 30°C. 
The mobile phase consisted of 0.1% aqueous H3PO4 and acetonitrile at 85:15 v/v (pH 2.10) 
with a flow rate of 1.0 mL/min. Each injection volume was 10 µL, and the UV detection 
was set at 205 nm. Under these conditions, the retention time of levetiracetam was 
approximately 5.4 minutes as shown in Figure 1a. 
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 Standards of levetiracetam solutions at 0.05, 0.10, 0.15, 0.20, and 0.25 mg/mL were 
prepared for calibration purpose. This range encompassed the expected concentrations of 
the diluted stability samples. Because it was cost prohibitive to purchase the pure drug 
substance of levetiracetam, the standards were prepared by diluting the 100 mg/mL 
commercial oral solutiona with purified water. The same lot of the levetiracetam oral 
solution was used as the one for the stability samples. For the practical purpose of this 
stability study, it was assumed that the drug concentration of this lot of oral solution was 
at the label claim of 100 mg/mL at the initiation of the study. Aliquots of the standard 
solutions were frozen for subsequent analysis at each time point in the study. It was also 
verified that there were no interfering excipients for the HPLC analysis (Figure 1a). A 
calibration curve was constructed by linear regression of the peak area of levetiracetam 
against levetiracetam concentration. The curve was found to be linear over the 
concentration range of the standards with an r2 = 0.998. The standards were injected three 
times at each stability time point to verify the precision of the method. The intra-day and 
inter-day coefficients of variation were within 1.11%.  
Forced Degradation Study 
 A short-term forced degradation study of levetiracetam was conducted under 
extreme pH, light, and oxidative stress conditions. This study was intended to verify the 
ability of the HPLC assay to separate the potential degradation products from the parent 
drug. Levetiracetam solutions of 0.2 mg/mL concentration were prepared in 0.5 N HCl, 0.5 
N NaOH, and 3% H2O2. These samples were incubated at 60°C for up to 72 hours. Three 
additional samples of 0.2 mg/mL levetiracetam solution in water were prepared and 
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exposed to 254 nm, 365 nm, and regular sun light for over 72 hours. The UV light at 254 
nm and 365 nm was generated by a standard lab hand-held UV lampf. 
 Among these samples, significant degradation was observed in only the two 
samples of extreme pH conditions. As shown in Figure 1, the degradation products were 
well separated from the parent molecule by the HPLC method, and no interfering peaks 
were observed. Therefore, the HPLC method was considered as stability-indicating and 
suitable for the stability evaluation of levetiracetam oral solution in the repackaged 
syringes.  
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RESULTS AND DISCUSSION 
 USP General Chapter 1136, previously 681, provides the guidance on non-
commercial repackaging of non-sterile liquid dosage forms into unit-dose containers.3 
According to this guidance, the manufacturer’s expiration date applies to the original 
container-closure system and is not intended to apply to the repackaged product. A suitable 
beyond-use-date (BUD) should be selected based on the nature of the drug, container, and 
storage condition in addition to the packaging and expiration information in the 
manufacturer’s product labeling.3  
 Levetiracetam is a relatively simple molecule with only two main functional groups, 
a 5-membered lactam ring and a terminal amide.1 Based on the physicochemical properties 
and the formulation ingredients described in the commercial product package insert,1 
repackaging levetiracetam oral solution in syringes is not expected to significantly alter the 
physical and chemical stability of the product over the desired 6-month BUD (not 
exceeding the original manufacturer’s expiry date). The solution product also contains 
paraben preservatives1 which should prevent microbial growth even after repackaging. 
 However, due to the high surface area to volume ratio of the syringe sample and 
the plastic nature of the oral syringes, there are several unique stability concerns. For 
example, there might be drug loss due to adsorption to the syringe and leachable from the 
syringe into the drug solution. In comparison to the original HDPE bottle, the thin plastic 
syringe barrel and weak closures may lead to significant water loss and/or increased 
exposure to oxygen over long-term storage. With these potential concerns, a stability study 
was deemed necessary to support the desired 6-month BUD of levetiracetam oral solution 
in oral syringes. Two syringe volumes, 1-mL and 10-mL, were included to bracket the 
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typical dose range. The 1-mL syringe represented the worst case scenario for the surface 
area to volume ratio. 
 At the initiation of the stability study, the levetiracetam 100 mg/mL oral solution 
appeared as a clear and colorless liquid. The initial sample pH and concentration values are 
reported in Tables 1 & 2. Over the six months of storage at refrigeration (2° – 8C) or room 
temperature (20° – 25C), all samples remained clear, colorless, and free of visible 
precipitation or microbial growth. No significant change in pH was observed for any 
samples (Table 1). The stability-indicating HPLC analysis also confirmed that all samples 
retained 97% – 108% of the initial concentration with no new peaks observed (Table 2). 
Overall, the levetiracetam 100 mg/mL oral solution was found to be stable in amber 
polypropylene oral syringes. 
 It is also important to note that the oral solution product was originally developed 
by UCB (Keppra) and approved by FDA in 2003.4 Currently, the generic product is 
available via multiple sources,4 and most formulations contain similar excipients as the 
brand name product.5 Therefore, the stability data generated in this study should be 
applicable to other generic products with similar excipient compositions.  
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FOOTNOTES 
a Levetiracetam oral solution, 100 mg/mL. Morton Grove Pharmaceuticals, Inc., Morton 
Grove, IL, NDC 60432-831-16, lot# 31086A. 
b Exacta-Med oral syringes with tips, Baxa Corporation, Englewood, CO. 
c SevenEasy pH meter, Mettler-Toledo Inc., Columbus, OH. 
d HPLC system, Model 2010A, Shimadzu Scientific Instruments, Marlborough, MA. 
e HPLC column, ODS AQ, 5 µm, 250 x 4.6 mm, YMC America, Inc., Allentown, PA. 
f UV Lamp, Spectroline Model ENF-240C, Spectronics Corporation, Westbury, NY. 
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Figure 1. HPLC chromatograms of (a) levetiracetam standard solution 0.2 mg/mL in water; 
(b) levetiracetam solution 0.2 mg/mL in 0.5 N HCl after 48 hours; (c) levetiracetam 
solution 0.2 mg/mL in 0.5 N NaOH after 24 hours. 
 
(a) 
 
 
(b) 
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Table 1. pH Stability Results of Levetiracetam 100 mg/mL Oral Solution Repackaged in Plastic Syringes (n = 3) 
 
Storage Temperature 
and Syringe Size 
Initial pH 
pH 
1-month 2-month 3-month 4-month 5-month 6-month 
2° – 8°C, 1 mL 
5.50  0.00 
5.57  0.03 5.61  0.01 5.54  0.01 5.47  0.02  5.49  0.01 5.53  0.02 
20° – 25°C, 1 mL 5.57  0.01 5.64  0.02 5.52  0.00 5.46  0.01 5.48  0.00 5.55  0.01 
2° – 8°C, 10 mL 
5.50  0.00 
5.57  0.01 5.57  0.02 5.51  0.01 5.46  0.01 5.51  0.01 5.57  0.01 
20° – 25°C, 10 mL 5.55  0.01 5.63  0.02 5.53  0.01 5.45  0.01 5.47  0.00 5.55  0.01 
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Table 2. HPLC Stability Results of Levetiracetam 100 mg/mL Oral Solution Repackaged in Plastic Syringes (n = 3) 
 
Storage Temperature 
and Syringe Size 
Initial Drug 
Concentration 
(mg/mL) 
% Remaining 
1-month 2-month 3-month 4-month 5-month 6-month 
2° – 8°C, 1 mL 
97.8  0.9 
102.7  0.2 102.9  1.0 106.2  2.2 102.8  0.1  103.4  0.5 105.2  0.8 
20° – 25°C, 1 mL 103.2  0.4 105.1  0.3 107.8  0.5 105.9  0.7 105.3  0.2 104.3  0.6 
2° – 8°C, 10 mL 
101.1  1.4 
99.1  0.4 101.0  2.9 104.2  1.0 100.6  1.0 101.7  1.5 98.6  1.3 
20° – 25°C, 10 mL 99.1  0.9 100.8  0.9 103.0  1.2 102.2  1.1 102.3  1.4 101.0  1.3 
 
